FDA — authorised 26 March 2019
- Marketing authorisation holder: NOVARTIS PHARMS CORP
- Status: approved
FDA authorised Mayzent on 26 March 2019
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 26 March 2019.
NOVARTIS PHARMS CORP holds the US marketing authorisation.